Ligand Pharmaceuticals

Royalty-based biopharma

LGND · Nasdaq · United States

Share price · LGND

$298.71+11.12 (+3.87%) 3M

close as of 2026-11-18 · 24h delayed · vol 381K (1.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LGND's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Oct 2026+3.1%
  2. 23 Jun 2026+6.6%
  3. 7 May 2026-9.6%
  4. 27 Apr 2026+4.5%
  5. 14 Apr 2026+8.9%
  6. 11 Mar 2026+4.2%

    Nothing announced by LGND that day or the session before.

  7. 13 Jan 2026-8.7%

Share of unusual movement by asset

For each asset, the share of LGND's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
VK2809
events and moves
2shown from 8 days
berdazimer (Zelsuvmi)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—35%
Sessions with no dated event—65%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
berdazimer(Zelsuvmi)
Approved
Nitric oxide releaseSmall molecule
Molluscum Contagiosum
Phase 2
Thyroid hormone receptor-betaSmall molecule
MASH / NASH

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$79M$2.8M$103M+ $391M short-term inv.$28M-$28M operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$64M$15M$1.0B+ $351M short-term inv.—$24M operating cash flowreport ↗
2026-Q1$52M$2.1M$115M+ $664M short-term inv.$13M$49M operating cash flowreport ↗
2025-Q3$115M$21M$139M+ $525M short-term inv.—$13M operating cash flowreport ↗
2025-Q2$48M$6.6M$68M+ $177M short-term inv.—$16M operating cash flowreport ↗
2025-Q1$45M$50M$48M+ $161M short-term inv.$42M-$25M operating cash flowreport ↗
2024-Q3$52M$5.7M$64M+ $156M short-term inv.$7.2M$37M operating cash flowreport ↗
2024-Q2$42M$5.3M$18M+ $209M short-term inv.$52M$13M operating cash flowreport ↗
2024-Q1$31M$6.0M$50M+ $261M short-term inv.—$19M operating cash flowreport ↗
2023-Q3$33M$5.5M$20M+ $171M short-term inv.$10M$7.7M operating cash flowreport ↗
2023-Q2$26M$6.8M$28M+ $191M short-term inv.—-$0.1M operating cash flowreport ↗
2023-Q1$44M$6.7M$89M+ $194M short-term inv.—$34M operating cash flowreport ↗
2022-Q4$50M$9.2M$45M+ $167M short-term inv.$17M$53M operating cash flowreport ↗
2022-Q3$66M$22M$4.1M+ $117M short-term inv.—$20M operating cash flowreport ↗
2022-Q2$57M$19M$5.3M+ $143M short-term inv.$0.9M$12M operating cash flowreport ↗
2022-Q1$46M$20M$15M+ $189M short-term inv.$15M$52M operating cash flowreport ↗
2021-Q4$56M$8.2M$20M+ $322M short-term inv.$5.4M$28M operating cash flowreport ↗
2021-Q3$65M$17M$23M+ $300M short-term inv.—$20M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$268M$81M$175M+ $559M short-term inv.—$49M operating cash flowreport ↗

Ligand Pharmaceuticals reported full-year 2025 revenue of $268.09M, up 60.4% YoY, with R&D spend of $81.18M, up 278.8% YoY. Cash and equivalents stood at $174.93M, and GAAP net income was $124.45M.

Management reiterated 2026 guidance of $245–$285M in total revenue and adjusted EPS of $8.00–$9.00. Key disclosed developments included positive Phase 3 results for Palvella’s Qtorin rapamycin, regulatory progress for Ohtuvayre, Filspari, and Tzield, UroGen’s discontinuation of UGN-301, and new royalty rights related to Xepi and lasofoxifene.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$167M$21M$72M+ $184M short-term inv.$1.0M$97M operating cash flowreport ↗
2023-FY$131M$25M$23M+ $147M short-term inv.—$50M operating cash flowreport ↗
2022-FY$196M$36M$45M+ $167M short-term inv.$8.3M$138M operating cash flowreport ↗
2021-FY$277M$69M$20M+ $322M short-term inv.—$79M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 151 sales ($36.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-12Zimmermann Martine · directorOpen-market sale2,000$318.17$636KForm 4
2026-11-12KOZARICH JOHN W · directorOpen-market sale500$325.00$163KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale500$319.99$160KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale844$320.00$270KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale646$320.00$207KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale10$320.02$3KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale500$320.10$160KForm 4
2026-11-10Aryeh Jason · directorOpen-market sale500$320.20$160KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 352 reporting institutions held 20.8M shares ($4.1B, 103.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.2,961,923$591.3M
2VANGUARD PORTFOLIO MANAGEMENT LLC1,100,267$219.7M
3JANUS HENDERSON GROUP PLC1,009,891$201.6M
4VANGUARD CAPITAL MANAGEMENT LLC848,089$169.3M
5Invesco Ltd.823,604$164.4M
6STATE STREET CORP778,856$155.5M
7FMR LLC596,127$119.0M
8NOMURA ASSET MANAGEMENT INTERNATIONAL INC.573,312$114.5M
9FRANKLIN RESOURCES INC573,177$114.4M
10Chicago Capital, LLC561,675$112.1M
11GEODE CAPITAL MANAGEMENT, LLC558,934$111.6M
12CONGRESS ASSET MANAGEMENT CO504,637$100.8M
13Stephens Investment Management Group LLC494,670$98.8M
14DIMENSIONAL FUND ADVISORS LP425,230$84.9M
15MASSACHUSETTS FINANCIAL SERVICES CO /MA/411,543$82.2M